Search results
Showing 31 to 45 of 680 results for kidney or kidneys or renal
Irreversible electroporation for treating renal cancer (HTG303)
Evidence-based recommendations on irreversible electroporation (IRE) for treating renal cancer. This involves using electrical pulses to kill cancer cells, applied directly to the tumour through special needles.
View recommendations for HTG303Show all sections
Sections for HTG303
Finerenone for treating chronic kidney disease in type 2 diabetes (TA877)
Evidence-based recommendations on finerenone (Kerendia) for stage 3 and 4 chronic kidney disease (with albuminuria) associated with type 2 diabetes in adults.
This indicator covers the percentage of patients on the CKD register and with an albumin to creatinine ratio (ACR) of 70 mg/mmol or more, without diabetes, who are currently treated with an ARB or an ACE inhibitor. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM247
This indicator covers the percentage of patients with a new diagnosis of CKD stage G3a-G5 (on the register, within the preceding 12 months) who had eGFR and ACR (urine albumin to creatinine ratio) measurements recorded within 90 days before or after diagnosis. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM216
Kidney conditions: CKD and lipid lowering therapies (IND231)
This indicator covers the percentage of patients with CKD, on the register, who are currently treated with a lipid-lowering therapy. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM213
Kidney conditions: CKD and renin–angiotensin system antagonists (IND130)
This indicator covers the percentage of patients on the chronic kidney disease (CKD) register who have hypertension and proteinuria and who are currently being treated with an angiotensin-receptor blocker or an angiotensin-converting enzyme inhibitor. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM84
Pembrolizumab for adjuvant treatment of renal cell carcinoma (TA830)
Evidence-based recommendations on pembrolizumab (Keytruda) for adjuvant treatment of renal cell carcinoma in adults.
This guideline sets out an antimicrobial prescribing strategy for acute pyelonephritis (upper urinary tract infection) in children, young people and adults who do not have a catheter. It aims to optimise antibiotic use and reduce antibiotic resistance.
Evidence-based recommendations on laparoscopic deroofing of simple renal cysts. This involves draining the cyst and removing part of the cyst wall through small cuts in the abdomen (keyhole surgery).
View recommendations for HTG145Show all sections
Sections for HTG145
Kidney conditions: CKD and blood pressure when ACR 70 or more (IND264)
This indicator covers the percentage of patients on the CKD register and with an albumin to creatinine ratio (ACR) of 70 mg/mmol or more, without moderate or severe frailty, in whom the last blood pressure reading (measured in the preceding 12 months) is less than 125/75 mmHg if using ambulatory or home monitoring, or less than 130/80 mmHg if monitored in clinic. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM248.
Obinutuzumab with mycophenolate mofetil for treating lupus nephritis (TA1131)
Evidence-based recommendations on obinutuzumab (Gazyvaro) with mycophenolate mofetil for treating lupus nephritis in adults.
Kidney conditions: CKD and blood pressure when ACR less than 70 (IND235)
This indicator covers the percentage of patients on the CKD register and with an albumin to creatinine ratio (ACR) of less than 70 mg/mmol, without moderate or severe frailty, in whom the last blood pressure reading (measured in the preceding 12 months) is less than 135/85 mmHg if using ambulatory or home monitoring, or less than 140/90 mmHg if monitored in clinic. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM217
Eculizumab for treating atypical haemolytic uraemic syndrome (HST1)
Evidence-based recommendations on eculizumab (Soliris) for treating atypical haemolytic uraemic syndrome in adults and children.
Percutaneous transluminal renal sympathetic denervation for resistant hypertension (HTG662)
Evidence-based recommendations on percutaneous transluminal renal sympathetic denervation for resistant hypertension. This involves inserting a device through the skin (percutaneous) into an artery in the thigh and then into the renal arteries (transluminal). It sends radio or sound waves to destroy the nerves in the renal arteries (sympathetic denervation). The aim is to lower blood pressure.
View recommendations for HTG662Show all sections
Evidence-based recommendations on vadadustat (Vafseo) for treating symptomatic anaemia in adults having dialysis for chronic kidney disease.